FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name ar Cochra (Last)	n John	Reporting Person*	(Middle)		3. E	Susuer Name and Ticker or Trading Symbol Aquestive Therapeutics, Inc. [AQST] Date of Earliest Transaction (Month/Day/Year)									elationship of Reporting F eck all applicable) Director Officer (give title below)			on(s) to Iss 10% Ov Other (s below)	vner	
C/O AQUESTIVE THERAPEUTICS, INC.				106	06/15/2021															
30 TECHNOLOGY DRIVE					<u> </u>															
						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					olicable	
(Street)		_												X	Form fil	ed by One	Repo	rting Perso	n	
WARRE	N N.	J	07059												Form fil Person	ed by Mor	e than	One Repor	rting	
(City)	(Si	tate)	(Zip)			Person														
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					Execution Date,		Code (Instr. 5)					5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership				
								Code	v	Amount	(A) o (D)	A) or D) Price		Transacti (Instr. 3 a	tion(s)			(Instr. 4)		
Common Stock													99,486			D				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	ate, T	1. Fransa Code (I 3)		of E		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amo of Securities Underlying Derivative Secur (Instr. 3 and 4)		Derivative Security		9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership ct (Instr. 4)		
				Code	Code	v	(A)	(D)	Date Exercisabl		Expiration Date	Title	Amoun or Number of Shares	r						
Stock Option (Right to Purchase)	\$4.04	06/15/2021			A		20,000		06/15/2022	2(1)	06/15/2031	Common Stock	20,00	0	\$0	20,00	0	D		

Explanation of Responses:

1. The shares underlying the options vest as follows: 100% of the underlying shares vest June 15, 2022, subject to Mr. Cochran's continuous service with the Issuer from the grant date through the applicable vesting date.

Remarks:

/s/ Lori Braender, as Attorney-06/17/2021

In-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.